The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...

The prescription pills, sold under the brand name Journavx and made by Vertex Pharmaceuticals, are taken twice a day and ...

U.S. officials have approved a new type of pain drug designed to eliminate the risks of addiction and overdose associated ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

The M9 positions MG in the premium electric MPV segment and will be offered exclusively through the brand's 'Select' dealerships MG to retail the premium M9 MPV via its new ‘Select’ dealerships.

Novo Nordisk (NVO) announced Friday that its popular obesity therapy, semaglutide, marketed as Wegovy, led to 20.7% weight loss over 72 weeks at a higher dose of 7.2 mg in a late-stage trial.

The late-stage trial of semaglutide, which it markets as Wegovy to treat obesity, showed that those who took a dose of 7.2 milligrams lost an average of 20.7% of their weight over 72 weeks.

Patients on the once-weekly 7.2 milligram dose of Novo's drug for 72 weeks lowered their weight by 20.7% during the trial, compared with 17.5% for the 2.4 milligram dose and 2.4% for the placebo.

These are cute-sy and boxy electric SUVs with a lot of appeal. They are positioned on a similar platform as MG Comet EV sold in India. Naturally, we are hoping Baojun Yep Plus will make its way to ...